Every milestone at Strides has left behind a footprint of achievement and success. And a story of the commitment, dedication and trust of our employees, customers and partners.


Joint Venture Arrangement with Vivimed Labs

Entered into a Joint Venture arrangement with Vivimed Labs Ltd to set up two Joint Venture Companies in India and Singapore, respectively.

The Joint venture will provide access to additional capacities to the tune of 1.5 billion tablets/ capsules per annum and a strong product pipeline. This arrangement will also help de-risking of manufacturing base of the Company.

Acquisition of Amneal Pharmaceuticals, Australia

Arrow Pharmaceuticals, a step-down subsidiary of the Company in Australia, acquired 100% stake in Amneal Pharmaceuticals, Australia, which is engaged in the business of selling generic pharmaceutical products in Australia.

The acquisition in intended to improve Arrow’s generics market share thereby expanding its first-line pharmacies to 1200+ stores and provide significant synergy opportunities with 100+ molecules being common with Arrow Portfolio.

Acquisition of Trinity Pharma, South Africa

Strides Pharma Asia, the Company’s wholly owned subsidiary in Singapore, acquired controlling stake in Trinity Pharma, a company incorporated in South Africa and engaged in the business of supply and distribution of generic pharmaceutical products to pharmaceutical retailers and providing services relating to regulatory and registration of products.

The acquisition will enable Strides to establish a presence in the high entry market of South Africa where product dossier approval takes more than 5 years; access to pipeline of more than 110 product dossiers and facilitate ARV launch in private non-tender market in South Africa.

Exit of India Brands Business

The Company exited from India Brand Business effective December 2017. The Company retains global rights for the divested portfolio, which have significant sales in Africa and will continue to grow the Company’s emerging market business.

Demerger of the Commodity API Business

Pursuant to a composite Scheme of Arrangement between the Company, SeQuent Scientific Limited and Solara Active Pharma Sciences Limited and their respective shareholders and creditors under section 230-232 of the Companies Act, 2013, the Company completed the demerger of its Company’s Commodity API Business to Solara.

Pursuant to the aforesaid Scheme, the Human API business of SeQuent was also demerged to Solara. Appointed Date and Effective Date for demerger was October 1, 2017 and March 31, 2018, respectively.


Arrow Pharmaceuticals Pty Ltd. (Arrow), a Wholly-owned Subsidiary Company in Australia entered into a 10-year supply partnership and trading platform agreement with Pharmacy Alliance, Australia's longest standing co-operative buying groups.

Divested Shasun Pharma Solutions Ltd, UK - CRAMS API Business

Acquired PediaCare brand from Moberg Pharma, Sweden for expanding the Company’s consumer health care portfolio

Exited from Probiotic Business effective March 31, 2017. The said Business was acquired from Medispan Limited in December 2015 Hived-off of Africa Generics Business as a Management Buyout to Africure Pharmaceuticals Limited, Mauritius effective March 30, 2017. Africure is a company owned by Mr. Sinhue Noronha, the erstwhile CEO of Africa business

Capped Strides investment in Stelis Biopharma Private Limited at USD 22.10 Million effective March 31, 2017.


Re-entered the Australian market in a leadership position under Arrow Pharmaceuticals.

Merger of Shasun Pharmaceuticals Limited, with the Company forming the new identity Strides Shasun Limited effective from November 19, 2015 (Appointed Date being April 1, 2015). Re-entered Australia in Leadership position through acquisition of generic pharmaceutical business from Aspen Pharmacare Holdings Limited (Aspen).

Strengthened the Emerging Market brand portfolio through acquisition of CNS division of erstwhile Ranbaxy from Sun Pharma, brands portfolio from Johnson & Johnson and majority stake in domestic branded business of Medispan

Acquired controlling stake in Universal Corporation, Kenya to gain access to fast growing key East African markets. The acquisition also provided access to one of the only two WHO Pre-Qualified sites in Sub-Saharana Africa

Strengthened the global Over the Counter (OTC) portfolio with the acquisition of Jointflex, Fergon and Vanquish brands from Moberg Pharma, Sweden and its affiliates

Strategic acquisition of Generic Partners Holdings, Australia for leveraging strong product development & registration capabilities and consolidating the R&D initiatives


Approval of scheme of amalgamation between Strides Arcolab Limited and Shasun Pharmaceuticals Ltd, approval date being April 1, 2015

Re-entered Australian market: In May 2015, the Company announced that Strides Pharma Global, Singapore and Strides (Australia) Pharma, Australia, signed definitive agreements with Aspen Pharmacare Holdings Limited, a company listed on the Johannesburg Stock Exchange to acquire a generic pharmaceutical business in Australia

The company entered into an arrangement with GMS Holdings, Jordan, for an investment of USD 21.90 Million for a 25.1% stake in Stelis Biopharma

Merger of Stelis Biopharma Private Limited with Inbiopro Solutions Private Limited. Effective date of merger being November 10, 2014

Acquired brand ‘Raricap’ and the India Branded Generic Business of Bafna Pharmaceuticals


Entered into definitive agreement for sale of “Agila specialties” division to Mylan Inc., USA in February, 2013

Biotech business re-branded as ‘Stelis Biopharma’

Completion of the sale of shares in Agila Specialties Private Limited to Mylan Laboratories Limited, for a consideration of USD 1.75 Billion. Completion date is December 5, 2013

Pay out a special dividend of Rs. 500.00 per share, resulting in a pre-tax distribution of USD 525 Million.

Revision in Credit Rating by Fitch from BBB+ to A+ on the overall performance of the Company

Credit Rating ICRA: Long term debt: A+. Short term debt: from A2 + to A1+ which is the highest in its category

Change of financial year from January-December to April-March


Collaboration with Gilead Sciences Inc to promote access to high-quality, low-cost generic versions of Gilead’s HIV medicine in developing countries

Funding from French Development Financing Institution of USD12.5 Million in the form of equity participation for a 20% stake in Strides’ African front-end arm

Consolidation of stake in Inbiopro from the initial holding of 70% to 96.79%

In February 2012, the Brazilian Sterile Penems facility received US FDA approval

The Company’s polish sterile facility received US-FDA approval

Acquired a USFDA approved Sterile Formulations facility situated at Hosur, Tamil Nadu from Star Drugs and Research Labs Limited

Joint Venture with Jamp Pharma Corporation, Canada through Agila Specialties Pharma Corporation, Canada

Collaboration with Eli Lilly to expand delivery of cancer medicines in the emerging markets


Pfizer Partnership for licensing agreements expanded to Emerging Markets with additional sterile injectable and oncolytic products. Completed Portfolio maximisation in established markets

Entered into an agreement with Malaysian Bio-XCell, an undertaking of the Government of Malaysia, through its wholly owned subsidiary Agila Specialties, Malaysia for the establishment of a customized facility to manufacture injectables

Divestment of the Australia and South East Asian Business of the Company to Watson Pharmaceuticals Inc., USA for AUD 375 Million resulting in divestment of its stake in Ascent Pharmahealth Limited


Crossed revenue of Rs. 1500 Crores

Collaborated with Pfizer to license and supply 40 off-patent products, largely oncology products for the USA market

Acquired Penems and Penicillin facilities in Campos, Brazil from Aspen Extended Pfizer transaction to cover Canada, Australia, European Union, Japan, New Zealand and Korea

Rebranded Specialty Division as Agila Specialties Private Limited

Acquired biotechnology company Inbiopro Solutions (70% stake) to enter the biologics space

Strides and Aspen restructure Oncology arrangements – Strides acquires 100% interest in Oncology business

Raised USD 100 Million (Rs.450 crore) through a Qualified Institutional Placement (QIP) issue

India Brands (Grandix) operations integrated into Strides with flagship brand 'Renerve', consolidating its leadership position

Medgene Pharmaceuticals Private Limited, a wholly owned subsidiary of the Company merged with Agila Specialties Private Limited in the Specialties Vertical pursuant to the Order of the Hon'ble High Court of Karnataka passed on February 6, 2010

Company redeemed outstanding USD 34 Million of the USD 40 Million FCCBs raised by the Company in the year 2005. The total payout for redeeming the Bonds was USD 46.50 Million as the Bonds were redeemable at a premium of 136.78%


Launched Ray of Life, a critical care division with a portfolio of specialty products addressing the hospital segment in India

Launched Starflu to treat H1N1

Restructured business divisions into Pharma (Pharma Generics and Branded Generics) and Specialty

Merged four of Companies Subsidiaries, i.e,. Global Remedies Limited, Grandix Pharmaceuticals Limited, Grandix Laboratories Limited and Quantum Remedies Private Limited within the Company

Redeemed USD 6 Million FCCB


Crossed revenue of Rs. 1000 Crores

Entered into a significant licensing deal with GlaxoSmithKline Pharmaceuticals for distribution in over 95 countries in emerging markets

Acquired controlling stake in Ascent PharmaHealth (55.46%), an Australian Stock Exchange listed company and a major generics player in Australia. The stake was acquired by Linkace Limited, a wholly owned subsidiary of the Company in Cyprus

Shutdown of soft gel facility in the USA


Acquired Grandix, a leading brand marketing company, to enter the Indian domestic market

Acquired 100% ownership of Farma Plus AS Norway

Collaborated with Aspen Group to set up an Oncology facility in India

Formed a joint venture with Sagent Pharmaceuticals for specialty products in USA

Ceded 50% ownership in LATAM operations to Aspen Group

Acquired Diaspa S.p.A USFDA approved fermentation facility including its business. This acquisition represented backward integration for significant part of Strides’ dosage form business

Acquired controlling stake (74%) in Strides Vital Nigeria Limited, Nigeria, through its wholly owned subsidiary Strides Africa Limited


Acquired controlling stake (70%) in Beltapharm SpA in Italy

Acquired 100% stake in Strides Arcolab Polska sp.z o.o., the Polish manufacturing facility of ICN Valeant

Acquired Drug Houses of Australia (Asia) Private Limited. (DHA), a leading player of branded generic pharmaceutical products in Singapore

Entered into an alliance with the Clinton Foundation for supplying AIDS drugs

Entered into a joint venture with Invent Farma in Spain to market products in the Spanish and Portuguese markets


Inaugurated the global research and development centre, Star Technology and Research or STAR at Bangalore

Crossed revenue of Rs.500 Crores.

Issued USD 40 Million, 0.5% FCCB, due 2010, at an initial conversion price of Rs. 358.70 per share with a fixed rate of exchange on conversion of Rs. 43.7667 = USD 1.00.


Listed on BSE Limited

Collaborated with Akorn Inc., USA to penetrate the US hospital market for sterile Products

Caryl Laboratories Limited, a wholly owned subsidiary of the Strides India was amalgamated with Global Remedies Limited another wholly owned subsidiary of Strides India pursuant to the Scheme of Amalgamation by the Hon'ble High Court of Karnataka and Hon'ble High Court of Judicature at Madras respectively


Joint Venture

The Company signed a Memorandum of Understanding with Ribbon S.r.I. Italy who were amongst the world’s largest Cephalosporin Penicillin manufacturers, for setting up a 50:50 Joint Venture Company to manufacture and market Cephalosporin formulations for the regulated markets

Hive off CRAM division

In accordance with the Scheme of Arrangement approved by the Hon’ble High Court of Mumbai vide its Order dated 4 October 2003, Strides India transferred the Contract Research and Manufacturing Division (“CRAM”) to its wholly owned subsidiary, Strides Research & Specialty Chemicals Limited (“SRSCL”) with effect from 1 April 2002. In terms of the said scheme, SRSCL allotted to Strides India 2,000,000 equity shares of Rs. 10 each.

Commenced development and manufacture of drugs against AIDS, TB and Malaria.


Acquired stake in Solara S.A. De C.V, Mexico and set up manufacturing plants in Brazil and Mexico

Amalgamation of Bombay Drugs Pharma Limited with the Company pursuant to sanction by Hon’ble High Court of Mumbai, vide their order dated September 26, 2001. Effective date of Amalgamation is April 1, 2000.


Acquired Bombay Drugs Pharma Limited, which had manufacturing facilities in Tarapur, Maharashtra and Panoli, Gujarat.


Acquired Strides Inc, Soft Gelatin facility in the USA

Strides India listed on the National Stock Exchange of India Limited in February 2000


Entered Latam market through investments in Infabra Industria Farmaceutica Brasileria Ltda, Brazil

Acquired Global Remedies, a manufacturing plant in Hosur, Tamil Nadu


Successful commissioning and stabilization of Soft Gelatin Capsule plant at KRS Gardens, Bangalore

Merger of Plama Laboratories Ltd., and Remed Laboratories (India) Ltd., into Strides, subject to respective High Court approvals effective from April 1, 1996.


Name changed to “Strides Arcolab Limited” effective 23 March 1997 to reflect the association of the Company with Arcolab SA, Switzerland in the pharmaceutical field


Acquired Plama Laboratories Limited, a bulk drug facility in Mangalore.

Acquired Remed Laboratories.

Commenced project to build new facility for tablets and capsules at KRS Gardens, Bangalore


New sterile manufacturing facility in Bangalore commenced production

Collaboration Agreement entered with Pharmagel Engineering s.r.l., Italy in January 1995 to set up a plant at KRS Gardens, Bangalore for manufacturing Soft Gelatin Capsules.


Conversion of “Strides Pharmaceuticals Private Limited” into a Public Company effective from May 23, 1994

Venture capital funding received from Schroders


Exports to Nigeria commenced


1990 Incorporation of the Company as “Strides Pharmaceuticals Private Limited”